|
|
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1643-1652.
Prepublished online as a Blood First Edition Paper on October 17, 2006; DOI 10.1182/blood-2006-05-023804.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto1,
Melissa Wright1,
Patrick Brown1,2,
Kyu-Tae Kim1,
Mark Levis1, and
Donald Small1,2
1 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD;
2 Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
Continuous treatment of malignancies with tyrosine kinase inhibitors (TKIs) may select for resistant clones (ie, imatinib mesylate). To study resistance to TKIs targeting FLT3, a receptor tyrosine kinase that is frequently mutated in acute myelogenous leukemia (AML), we developed resistant human cell lines through prolonged coculture with FLT3 TKIs. FLT3 TKI-resistant cell lines and primary samples still exhibit inhibition of FLT3 phosphorylation on FLT3 TKI treatment. However, FLT3 TKI-resistant cell lines and primary samples often show continued activation of downstream PI3K/Akt and/or Ras/MEK/MAPK signaling pathways as well as continued expression of genes involved in FLT3-mediated cellular transformation. Inhibition of these signaling pathways restores partial sensitivity to FLT3 TKIs. Mutational screening of FLT3 TKI-resistant cell lines revealed activating N-Ras mutations in 2 cell lines that were not present in the parental FLT3 TKI-sensitive cell line. Taken together, these data indicate that FLT3 TKI-resistant cells most frequently become FLT3 independent because of activation of parallel signaling pathways that provide compensatory survival/proliferation signals when FLT3 is inhibited. Anti-FLT3 mAb treatment was still cytotoxic to FLT3 TKI-resistant clones. An approach combining FLT3 TKIs with anti-FLT3 antibodies and/or inhibitors of important pathways downstream of FLT3 may reduce the chances of developing resistance.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Bodo, L. Durkin, and E. D. Hsi
Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology
J. Histochem. Cytochem.,
July 1, 2009;
57(7):
701 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Breitenbuecher, B. Markova, S. Kasper, B. Carius, T. Stauder, F. D. Bohmer, K. Masson, L. Ronnstrand, C. Huber, T. Kindler, et al.
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Blood,
April 23, 2009;
113(17):
4063 - 4073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhou, C. Bi, J. V. Janakakumara, S.-C. Liu, W.-J. Chng, K.-G. Tay, L.-F. Poon, Z. Xie, S. Palaniyandi, H. Yu, et al.
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Blood,
April 23, 2009;
113(17):
4052 - 4062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1110 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sallmyr, J. Fan, K. Datta, K.-T. Kim, D. Grosu, P. Shapiro, D. Small, and F. Rassool
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Blood,
March 15, 2008;
111(6):
3173 - 3182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
